Clover Health Investments, Corp. /De (CLOV) Stock Price & Analysis
Clover Health Investments, Corp. /De (CLOV) rose 9.44% to USD 4.29 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.
CLOV last closed at USD 3.92; the session ranged USD 3.93–4.44 on volume of 15,017,041 shares. Market capitalization is $2.26B, with a 52-week range of USD 1.58–4.44 (NMS). Source: Nexqual, June 9, 2026 at 23:49 UTC.
Key Statistics (as of June 9, 2026 at 23:49 UTC)
| Price | USD 4.29 |
|---|---|
| Change | ▲ 9.44% (up) |
| Previous Close | USD 3.92 |
| Open | USD 3.94 |
| Day Range | USD 3.93 – 4.44 |
| 52-Week Range | USD 1.58 – 4.44 |
| Volume | 15,017,041 shares |
| Market Cap | $2.26B |
| Exchange | NMS |
Technical Analysis (CLOV)
Nexqual's technical model rates CLOV "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.95 (neutral) |
| vs SMA50 | Above (USD 2.87) |
| MACD | 0.32 (positive) |
Analyst Ratings (CLOV)
Wall Street analysts rate CLOV "Buy" based on 3 analysts, with a mean price target of USD 3.48 (range USD 2.75–4.2), per Nexqual as of June 9, 2026 at 23:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3.48 |
| High Target | USD 4.2 |
| Low Target | USD 2.75 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (CLOV)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.05 |
| Revenue Estimate | $728.27M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.07 vs est 0.07 ▲ beat |
| 2025-12-31 | USD -0.05 vs est -0.05 ▲ beat |
| 2025-09-30 | USD 0 vs est 0.02 ▼ miss |
| 2025-06-30 | USD 0.03 vs est 0.03 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financials & Fundamentals (CLOV)
| Total Revenue | $2.21B |
|---|---|
| Revenue Growth (YoY) | +62.00% |
| Gross Margin | +18.36% |
| Operating Margin | +3.65% |
| Profit Margin | -2.58% |
| ROE | -16.86% |
| Current Ratio | 1.33 |
| Total Cash | $203.54M |
| Total Debt | $0 |
| Free Cash Flow | $75.08M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financial Health Score (CLOV)
Nexqual rates Clover Health Investments, Corp. /De's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:49 UTC.
| Growth | Strong — Revenue +40% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 18%, operating 4% |
| Balance Sheet | Mixed — $204M cash, no debt |
| Cash Flow | Mixed — FCF $75M, slim 3.9% margin |
| Efficiency | Critical — ROE -17%, ROA -5.6% |
Ownership (CLOV)
| Insider Ownership | +4.41% |
|---|---|
| Institutional Ownership | +30.01% |
| Shares Outstanding | 430.97M |
| Float | 408.71M |
| Short % of Float | +9.00% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Leadership (CLOV)
Clover Health Investments, Corp. /De is led by Andrew Toy (age 46), Co-Founder, CEO & Director, per Nexqual as of June 9, 2026 at 23:49 UTC.
| Co-Founder, CEO & Director | Andrew Toy (age 46) |
|---|---|
| Co-Founder & Executive Chairman | Vivek Garipalli (age 46) |
| Interim Chief Financial Officer | Clay Thornton (age 35) |
Major Backers & Investors (CLOV)
Notable institutional backers of Clover Health Investments, Corp. /De include Fidelity, Charles Schwab Investment Management, Inc., PNC Financial Services Group, Inc., according to Nexqual as of June 9, 2026 at 23:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.43% |
| Charles Schwab Investment Management, Inc. | 1.23% |
| PNC Financial Services Group, Inc. | 0.87% |
| Renaissance Technologies | 0.79% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.4% |
| Vanguard Group | 9.4% |
| Geode Capital | 2.33% |
| State Street | 2.22% |
| Dimensional Fund Advisors | 0.79% |
| Northern Trust | 0.77% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
From Clover Health Investments, Corp. /De's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Offers integration into provider workflows via EHRs We have made significant investments into extending our proprietary technology platform, enabling Clover Assistant functionality to be embedded quickly and seamlessly into major EHR systems, including Epic, Cerner, Athena and others.
- During 2024, the Company launched Counterpart Health, Inc., a new Software-as-a-Service ("SaaS") and Tech Enabled Services Solution to bring the power of Clover Assistant technology to external payors and providers serving the Medicare eligible population.
- Our proprietary technology platform is at the center of the Company's technology-first approach to driving better care management.
- Clover Assistant identifies opportunities for improvement in clinical quality gaps, including those prioritized by Centers for Medicare & Medicaid Services' ("CMS") Star Ratings Program (plan performance measures that drive bonus payments for plan providers), such as prescription drug adherence, regular cancer screenings and the annual flu shot.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SKLZ | Skillz Inc. | USD 8.81 | ▲ 4.51% |
| FUBO | fuboTV Inc. | USD 9.73 | ▲ 1.99% |
| SNDL | SNDL Inc. | USD 1.46 | ▲ 2.82% |
| BB | BlackBerry Limited | USD 8.84 | ▼ 6.06% |
| WKHS | Workhorse Group, Inc. | USD 3.17 | ▼ 3.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.